Capsule Commentary on Patrick et al., Trends in Insulin Initiation and Treatment Intensification among Patients with Type 2 Diabetes by Jornayvaz, François
CAPSULE COMMENTARIES
Capsule Commentary on Patrick et al., Trends in Insulin Initiation
and Treatment Intensification among Patients with Type 2 Diabetes
François R. Jornayvaz, M.D.
Service of Endocrinology, Diabetes, Hypertension and Nutrition, Geneva University Hospitals, Geneva, Switzerland.
J Gen Intern Med 29(2):356
DOI: 10.1007/s11606-013-2676-x
© Society of General Internal Medicine 2013
T his study by Patrick et al.
1 investigated the pattern of
insulin initiation, as well as treatment intensification,
among patients with type 2 diabetes compared to American
Diabetes Association (ADA) and European Association for
the Study of Diabetes (EASD) guidelines. Although this
observational study may not be representative of the general
population, as the 7,932 studied patients were derived from
a single commercial insurance company from a single state,
the reported data are relevant to the treatment of type 2
diabetes for both primary care physicians and specialists.
The main finding was that insulin was frequently initiated
without the withdrawal of sulfonylureas or meglitinides, as
recommended by the guidelines. Moreover, sulfonylureas
were started in 29 % and meglitinides in 11 % of patients
following insulin initiation. This is concerning, given the
important risk of hypoglycemia when combining these
antidiabetic agents. Furthermore, insulin and hypoglycemic
agents represent, respectively, the number two and number
four causes of emergency hospitalizations in older Ameri-
cans,2 and hypoglycemia was thought to be the cause of
excess death in the ACCORD trial.3
Only one-third of patients benefitted from treatment
intensification after insulin initiation, suggesting suboptimal
care. However, HbA1c levels were not available. Finally, a
quarter of patients discontinued insulin following initiation.
This might reflect either poor compliance, possibly due to
lack of knowledge or side effects, or the transient need for
insulin, such as during steroid use or severe illness.
It is uncertain whether endocrinologists would do better;
in this study, only 17 % of patients were seen by
specialists,1 though there is data that endocrinologists are
more likely to intensify diabetes treatment and initiate
insulin in type 2 diabetic patients.4 This study suggests that
a significant portion of type 2 diabetics being initiated on
insulin are continued on hypoglycemic agents, notably
sulfonylureas and meglitinides, a potentially hazardous
practice and in discordance with ADA/EASD guidelines.5
Whether this reflects under-appreciation of the hazards of
hypoglycemia, inadequate training and knowledge, or some
other factor is unknown and deserving of further research.
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